Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study - Takeaways - MDSpire

Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study

  • By

  • Lili Cheng

  • Dong Liang

  • Jing Jia

  • Runfeng Zhang

  • Yang Yang

  • Peng Liu

  • Hongli Sun

  • Xiaoqi Qin

  • Yanping Ma

  • Yin Wu

  • Hua Wang

  • Junling Zhuang

  • March 10, 2026

  • 0 min

Share

  • 1

    Quadruplet therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRd) shows promise for high-risk multiple myeloma patients.

  • 2

    The study involved 100 patients receiving D-VRd and 221 historical controls treated with VRd, focusing on efficacy and safety outcomes.

  • 3

    High-risk cytogenetic abnormalities (HRCAs) significantly impact prognosis, with ultra-high-risk patients showing poorer outcomes.

  • 4

    D-VRd demonstrated superior progression-free survival compared to VRd in patients with high-risk multiple myeloma.

  • 5

    The study highlights the urgent need for further validation of quadruplet therapy in real-world settings to improve long-term prognosis.

Original Source(s)

Efficacy of Quadruplet Therapy with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone as Initial Treatment for High-Risk Multiple Myeloma Patients in China: Findings from a Multi-Center Real-World Study

  • by Lili Cheng, Dong Liang, Jing Jia, Runfeng Zhang, Yang Yang, Peng Liu, Hongli Sun, Xiaoqi Qin, Yanping Ma, Yin Wu, Hua Wang, Junling Zhuang

  • March 10, 2026

Related Content

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside

An ASCO preview: What to watch for at cancer research’s big meeting

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis